Standard BioTools
LAB
141 hedge funds and large institutions have $543M invested in Standard BioTools in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 40 increasing their positions, 45 reducing their positions, and 22 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
13% more capital invested
Capital invested by funds: $480M → $543M (+$62.5M)
2.53% more ownership
Funds ownership: 73.23% → 75.76% (+2.5%)
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
2% less funds holding
Funds holding: 144 → 141 (-3)
11% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 45
21% less call options, than puts
Call options by funds: $72K | Put options by funds: $91K
Top Buyers
| 1 |
CC
Casdin Capital
New York
|
+$14.3M |
| 2 |
HBWM
Hollow Brook Wealth Management
Katonah,
New York
|
+$10.8M |
| 3 |
Morgan Stanley
New York
|
+$4.53M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$3.19M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$3.13M |
Top Sellers
LAB Hedge Fund Activity: Q3 2024 in Review
141 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2024, worth a combined $543M — up 13% from $480M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of LAB and 21 opened new positions — a net loss of 1 holder — while 45 trimmed existing stakes and 40 added.
The largest buyer was Casdin Capital, adding an estimated $14.3M. The largest seller was ARK Investment Management, cutting an estimated $7.3M.
- 141 institutional investors held Standard BioTools (LAB) as of Q3 2024, down from 144 in Q2 2024.
- Funds reported $543M of Standard BioTools stock for Q3 2024, up 13% quarter-over-quarter.
- 21 funds opened new Standard BioTools positions in Q3 2024 and 22 closed out, a net change of -1 holder.
- The largest Standard BioTools buyer in Q3 2024 was Casdin Capital, an estimated $14.3M added.
- The largest Standard BioTools seller in Q3 2024 was ARK Investment Management, an estimated $7.3M sold.
Based on aggregated 13F filings for Q3 2024.